A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Inclusion Criteria:

• Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria:

• EASI≥16 at Screening and Baseline visits;

• Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;

  • 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits;

• Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline;

Exclusion Criteria:

• Not enough washing-out period for previous therapy.
• Concurrent disease/status which may potentially affect the efficacy/safety judgement.
• Organ dysfunction.
• Pregnancy.
• Other.